Bill & Melinda Gates Foundation

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Immorna is a biotechnology company focused on developing RNA-based therapeutics and vaccines. The company employs various RNA platforms, including conventional, self-replicating, and circular RNA, to create innovative treatments. Immorna has established a comprehensive central management console for RNA synthesis, purification, and analytical testing, which facilitates both clinical and commercial development. Additionally, the company has developed advanced screening tools and a range of RNA delivery vehicles, such as polymers and lipid nanoparticles, incorporating proprietary ionizable cationic lipids. This robust infrastructure positions Immorna to contribute significantly to the field of RNA therapeutics.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.

Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.

Corner Therapeutics is a biotechnology research company focused on immunotherapy. It specializes in developing technologies that stimulate exceptional memory T cells to achieve lifelong immunity. The company utilizes a versatile dendritic cell hyperactivation platform that induces strong T-cell responses, aiming to provide robust and durable immunity against a wide range of cancers and infectious diseases. By enhancing T-cell activation, Corner Therapeutics seeks to enable healthcare providers to promote lasting immunity and optimize immune regulation.

Antibody Solutions provides antigen design, polyclonal antibody generation, research and drug development for biopharmaceutical companies.

Sail Biomedicines is a flagship pioneering company that is developing tomorrow's medicines today using life's language. Sail's platform combines first-in-class translatable circular RNA technology (Endless RNATM or eRNA) with unique programmable nanoparticles based on natural components to thoroughly program medications for the first time.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

VitriVax is a biotechnology startup based in Boulder, Colorado, focused on developing an innovative vaccine formulation platform. The company utilizes its proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology to create vaccines that are more effective, affordable, and accessible worldwide. This technology addresses the challenges associated with vaccine stability and administration by enabling the development of thermostable, single-shot vaccines that can effectively incorporate both prime and booster doses. VitriVax's advancements in vaccine formulation aim to eliminate barriers to global vaccination, ultimately enhancing immune responses for a broad range of medical indications. The company has received significant funding, including over $5 million from various sources such as the National Institutes of Health, the National Science Foundation, and the Bill and Melinda Gates Foundation, to support its mission.

STRM.BIO is a biotechnology company focused on enhancing gene therapy delivery through the use of extracellular vesicles (EVs). These natural carriers, which transport nucleic acids and proteins, offer innate targeting capabilities and can be mass-produced efficiently. By leveraging EVs, STRM.BIO aims to create a new class of therapeutics that not only introduces novel treatments but also improves the effectiveness of existing therapies. The company's approach seeks to simplify and enhance the safety of gene therapy delivery directly to patients, fulfilling the potential of this innovative medical field.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

Aegis Life is a biotechnology company focused on advancing nucleic acid delivery technology, specifically through its proprietary platform known as fusogenix PLV. This technology, developed over two decades, is designed to facilitate the rapid development and commercialization of vaccines and therapeutics aimed at preventing and treating infectious diseases. Aegis Life's innovative approach supports the pharmaceutical industry in accelerating the discovery, clinical development, and manufacturing processes for vaccines and treatments, particularly in response to emerging health threats such as COVID-19.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

Aspen Pharmacare Holdings Limited is a global pharmaceutical company headquartered in Durban, South Africa, specializing in the manufacture and supply of both branded and generic pharmaceutical products. It operates primarily through two segments: Commercial Pharmaceuticals and Manufacturing. Aspen offers a diverse range of products, including general anaesthetics, muscle relaxants, cytotoxic medications, and injectable anticoagulants, particularly focusing on low molecular weight heparins and Xa inhibitors. The company also engages in the contract production and supply of active pharmaceutical ingredients (APIs) and finished pharmaceuticals for third parties. With a presence in over 150 countries, Aspen serves various markets, including South Africa, Australia, and several nations across Europe and Asia. Its extensive capabilities in manufacturing encompass both API and finished dosage forms, addressing a wide array of therapeutic needs. Founded in 1850, Aspen has expanded its reach significantly through strategic acquisitions, enhancing its footprint in emerging markets and contributing to a diverse portfolio of healthcare solutions.

ExploRNA Therapeutics creates revolutionary advancements in the use of mRNA as a therapeutic platform, implements those ideas into distinct therapeutic programs, and provides technology, a therapeutic platform, and medicines to pharmaceutical partners.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, it has developed the proTL synthetic DNA platform, which allows for the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach supports various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. The company boasts a skilled scientific and drug development team, led by founder and CEO Jonny Ohlson, and includes experienced professionals such as Clive Dix and John Tite. Touchlight has established partnerships with several leading academic institutions, including Imperial College London and the University of Pennsylvania, to advance its research and development efforts. The company has successfully patented its synthetic DNA platform and demonstrated therapeutic proof-of-principle through collaboration with these academic partners.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

Yemaachi Biotechnology is focused on advancing the diagnosis and treatment of cancer through innovative therapeutic technologies. The company employs immunogenomics, bioinformatics, and artificial intelligence to enhance the development of effective cancer detection and treatment strategies. By leveraging these advanced methodologies, Yemaachi aims to lower the economic burden of cancer and improve patient outcomes through more accurate and efficient therapeutic solutions.

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in San Jose, California, that specializes in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to address life-threatening infections. The company’s lead product candidate, AR-301, is currently undergoing Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis is advancing several other candidates, including AR-105, a fully human IgG1 mAb in Phase II trials targeting the gram-negative bacterium P. aeruginosa, and AR-101, which is also in Phase II trials for hospital-acquired pneumonia caused by the same pathogen. Other projects in development include AR-401, AR-201, and AR-501, which target various serious infections. Aridis employs proprietary technology platforms to identify and manufacture potent mAbs derived from patients who have successfully overcome infections, enabling the production of therapeutics that are optimized for efficacy without requiring genetic modification. Founded in 2003, Aridis Pharmaceuticals is committed to providing innovative solutions for critical infections.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Providence Therapeutics is a biotechnology company that develops a personalized mRNA cancer vaccine designed to treat advanced ovarian cancer. The company's vaccine identifies tumor mutations and elicits an immune response against the tumor cells, enabling users to treat themselves and live life to the fullest. It aims to provide safe and effective medicines for people suffering from diseases with unmet medical needs. Scott Leary, Eric Marcusson, and Bradley Sorenson established the company in Toronto, Ontario in 2015.

Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders. Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations. The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties. Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes. Finally, Titan is also entitled to royalty revenue of 8-10% of net sales of Fanapt® (iloperidone), an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG (“Novartis”) under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension). Substantially all of this future royalty revenue has been sold to Deerfield Management (“Deerfield”), a healthcare investment fund, in exchange for cash and debt considerations which have been used to advance the development of Probuphine and for general corporate purposes.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Sunflower Therapeutics is a biotechnology company focused on advancing protein manufacturing solutions to enhance global access to biological medicines. By employing strain engineering and integrated process development, the company aims to create efficient, automated systems for protein production. These innovations are designed to support a wide range of applications, including new medicines and food products, allowing clients to significantly reduce the time and costs associated with developing and manufacturing biologics. Sunflower Therapeutics emphasizes values such as wellness, integrity, ethics, equity, community, and efficiency in its operations, reflecting its commitment to benefiting the global population.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Atomwise, Inc. is a biotechnology company based in San Francisco that specializes in using deep learning artificial intelligence for small molecule drug discovery. Founded in 2012, Atomwise developed the AtomNet platform, which enables virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical approach that leverages experimental affinity measurements and protein structures. The company focuses on addressing over 600 unique disease targets and has established partnerships with more than 250 organizations, including pharmaceutical and biotechnology firms. Atomwise's technology has been recognized for its ability to unlock previously undruggable targets, and the company has raised significant funding to support its mission of accelerating drug discovery and development.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and preventing diseases associated with human papillomavirus (HPV), cancer, and various infectious diseases. The company's proprietary SynCon immunotherapy design enhances the immune response against cancerous cells and provides broad protection against multiple pathogens. Inovio is actively conducting clinical studies for its DNA medicines, particularly for HPV-related precancers and cancers, as well as other diseases such as glioblastoma, prostate cancer, HIV, and COVID-19. Its lead candidate, VGX-3100, is in Phase 3 trials for treating precancerous cervical dysplasia linked to high-risk HPV types. The company has established partnerships with various organizations, including major pharmaceutical companies and research institutions, to advance its research and development efforts. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals is recognized for its innovative approach to immunotherapy and gene therapy.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.

Almac Group is a contract development and manufacturing organization that provides a comprehensive array of services to pharmaceutical and biotech companies worldwide. Established over 40 years ago and privately owned, the company offers research and development, biomarker discovery, active pharmaceutical ingredient (API) manufacturing, formulation development, clinical trial supply, and commercial-scale manufacturing, among other services. With its headquarters in Craigavon, Northern Ireland, Almac has expanded its operations to various locations, including the UK, Ireland, the US, and Asia. The company employs over 4,500 staff and is committed to continuous investment in its offerings, which encompass biomarker and companion diagnostics, clinical trial data management, and biocatalytic API manufacture. Additionally, Almac Discovery, a division of the group, focuses on innovative oncology research and the early-stage development of novel cancer treatments in partnership with pharmaceutical companies.

RJH Biosciences is a biotechnology company specializing in the development of transfection reagents and delivery systems designed to transport various types of nucleic acids into human cells and cell lines. The company emphasizes innovative solutions for addressing blood cancers and modifying immune cells, thereby enhancing the therapeutic potential of nucleic acids in medical applications. RJH Biosciences distributes its products through its website and is also engaged in projects aimed at developing new medical treatments.

Enesi Pharma is an innovative pharmaceutical company developing novel products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare. The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organizations.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

AbCellera is an antibody discovery and development company focused on overcoming the limitations of traditional discovery methods. By utilizing its integrated platform, AbCellera's experts rapidly search a diverse array of antibodies to identify the most effective candidates for clinical development. This streamlined approach allows for faster movement to clinical trials, ultimately benefiting patients sooner. The company has a strong track record of collaborating with both emerging biotechnology firms and established pharmaceutical companies, providing optimized solutions tailored to their needs. AbCellera employs proprietary technology and advanced data science to enhance its antibody discovery process, positioning itself as a strategic partner in the biopharmaceutical industry.

Lyell Immunopharma is a clinical-stage company focused on developing innovative T cell therapies for patients with solid tumors. The company aims to overcome major challenges in adoptive T cell therapy, such as T cell exhaustion and the loss of durable stemness, which affects the efficacy of treatment. To achieve this, Lyell employs proprietary ex vivo genetic and epigenetic reprogramming technologies, known as Gen-R and Epi-R, to enhance T cell functionality. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, which are designed to provide improved and lasting therapeutic outcomes for patients.

Evolve Biosystems, Inc. is a biotechnology company based in Davis, California, focused on developing and marketing probiotic-based biotherapeutics aimed at establishing, restoring, and maintaining a healthy human microbiome. The company specializes in addressing gut dysbiosis across the human life cycle, particularly in newborns during their first six months of life. Evolve Biosystems utilizes a platform that combines specific probiotic bacteria with prebiotic oligosaccharides to create effective delivery systems. Their products include consumer-directed solutions for home use as well as specialized formulations for neonatal intensive care units. In addition to human health, the company also applies its discovery platform to address similar microbiome issues in production animals. Evolve Biosystems was incorporated in 2011.

Scripps Research is a prominent independent, not-for-profit organization dedicated to advancing biomedical research aimed at enhancing human health. Established from the Scripps Metabolic Clinic in 1924, it has grown into one of the largest institutions of its kind, employing around 3,000 individuals across its campuses in La Jolla, California, and Jupiter, Florida. The institute is recognized for its significant contributions to the biomedical sciences, including the development of new treatments for various diseases such as cancer, rheumatoid arthritis, and hemophilia. Scripps Research is home to renowned scientists, including three Nobel laureates, who engage in cutting-edge research. Additionally, its graduate program in biology and chemistry is highly regarded, consistently ranking among the top ten programs in the United States.

Novartis is a global healthcare company headquartered in Switzerland, dedicated to addressing the evolving needs of patients worldwide through the development and manufacturing of innovative pharmaceuticals. The company focuses on a wide range of therapeutic areas, including oncology, rare diseases, neuroscience, immunology, respiratory, and cardio-metabolic conditions. Novartis is also active in medical nutrition, providing specialized nutritional solutions for individuals with specific dietary needs. Additionally, its animal health division develops advanced medicines aimed at improving the health and welfare of pets, farm animals, and farmed fish. The Genomics Institute of the Novartis Research Foundation plays a crucial role in bridging basic science and preclinical drug discovery, employing nearly 600 scientists to enhance drug development processes. Through its diverse portfolio and commitment to research, Novartis aims to transform patient care and improve health outcomes globally.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

AbCellera is an antibody discovery and development company focused on overcoming the limitations of traditional discovery methods. By utilizing its integrated platform, AbCellera's experts rapidly search a diverse array of antibodies to identify the most effective candidates for clinical development. This streamlined approach allows for faster movement to clinical trials, ultimately benefiting patients sooner. The company has a strong track record of collaborating with both emerging biotechnology firms and established pharmaceutical companies, providing optimized solutions tailored to their needs. AbCellera employs proprietary technology and advanced data science to enhance its antibody discovery process, positioning itself as a strategic partner in the biopharmaceutical industry.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at enhancing global access to biotherapeutics. The company focuses on innovative and integrated technologies that streamline the design, development, and manufacturing processes of biologics. Its key strengths lie in antibody discovery, molecular design, and the design of manufacturing processes and facilities. By leveraging scientific expertise and machine learning-driven technologies, Just Evotec Biologics provides clients with comprehensive solutions that accelerate biotherapeutic development while significantly lowering manufacturing costs.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader that focuses on researching, developing, manufacturing, and marketing innovative medicines. The company specializes in a range of therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases. With its commitment to improving patient outcomes, Takeda is dedicated to delivering advanced pharmaceuticals and therapeutics, as well as vaccines. Founded in 1781 and headquartered in Japan, Takeda operates worldwide, with significant research and development facilities in locations such as Cambridge, Massachusetts, and San Diego, California. The company also engages in strategic investments through its venture capital arm, which supports early-stage companies and technologies that align with its therapeutic focus, fostering collaborations that leverage its extensive R&D capabilities. Takeda's mission is to enhance the quality of life for patients globally through continuous innovation and excellence in healthcare.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

CureVac is a clinical-stage biopharmaceutical company based in Germany, focused on developing vaccines and therapies utilizing messenger RNA (mRNA). Founded in 2000, the company’s innovative approach involves using mRNA as a data carrier to instruct the body to produce proteins that can combat various diseases. CureVac's pipeline includes novel mRNA-based cancer immunotherapies, prophylactic vaccines for infectious diseases, and molecular therapies aimed at enhancing the body’s production of therapeutic proteins. Its most advanced candidate, CV9104, is currently in Phase IIb clinical trials for prostate cancer treatment. Additionally, CureVac has collaborated with GSK to create second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, while exploring other mRNA vaccine applications in oncology and various therapeutic areas.

Novavax, Inc. is a late-stage biotechnology company focused on the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases. Its lead vaccine candidates include ResVax, designed to protect infants from respiratory syncytial virus (RSV) through maternal immunization, and NanoFlu, targeted at treating seasonal influenza in older adults. Both candidates utilize Novavax's proprietary Matrix-M adjuvant to enhance immune responses. In addition, the company is advancing an RSV F vaccine for older adults and children, and it is developing nanoparticle vaccines against the Ebola virus and a combination respiratory vaccine for influenza and RSV. Novavax is also working on a COVID-19 vaccine, NVX-CoV2373, in collaboration with Takeda Pharmaceutical Company for development and commercialization. Established in 1987 and headquartered in Gaithersburg, Maryland, Novavax utilizes its recombinant technology platform to create highly immunogenic nanoparticles to address urgent global health needs.

CureVac is a clinical-stage biopharmaceutical company based in Germany, focused on developing vaccines and therapies utilizing messenger RNA (mRNA). Founded in 2000, the company’s innovative approach involves using mRNA as a data carrier to instruct the body to produce proteins that can combat various diseases. CureVac's pipeline includes novel mRNA-based cancer immunotherapies, prophylactic vaccines for infectious diseases, and molecular therapies aimed at enhancing the body’s production of therapeutic proteins. Its most advanced candidate, CV9104, is currently in Phase IIb clinical trials for prostate cancer treatment. Additionally, CureVac has collaborated with GSK to create second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, while exploring other mRNA vaccine applications in oncology and various therapeutic areas.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

BlueWillow Biologics, a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, specializes in the development of intranasal vaccines and anti-infective products utilizing its patented nanotechnology platform. The company's innovative NanoStat vaccine technology incorporates a unique oil-in-water nanoemulsion, allowing for the effective delivery and adjuvant of various antigens. BlueWillow focuses on vaccines for respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, and HIV, as well as providing NanoBio Protect, a nasal antiseptic solution. The company also has a licensing agreement with Merck for the use of its adjuvant in intranasal vaccines for respiratory syncytial virus (RSV) and seasonal influenza. Founded in 1999 as a spin-off from the University of Michigan, BlueWillow Biologics aims to enhance mucosal immunity through its advanced vaccine technology.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.